|
1) Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes(Lond). 2008; 32 Suppl 7: S13-8
|
|
|
|
|
2) Lazar MA. The humoral side of insulin resistance. Nat Med. 2006; 12: 43-4
|
|
|
|
|
3) Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-808
|
|
|
|
|
|
4) Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112: 1821-30
|
|
|
|
|
|
5) Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112: 1785-8
|
|
|
|
|
|
6) Spranger J, Kroke A, Möhlig M, et al. Adipo-nectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361: 226-8
|
|
|
|
|
|
7) Kumada M, Kihara S, Sumitsuji S, et al; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coro-nary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23: 85-9
|
|
|
|
|
|
8) Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adi-pose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006; 281: 26602-14
|
|
|
|
|
|
9) Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adi-pose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006; 116: 1494-505
|
|
|
|
|
|
10) Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006; 116: 115-24
|
|
|
|
|
|
11) Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005; 25: 2062-8
|
|
|
|
|
|
12) Suganami T, Tanimoto-Koyama K, Nishida J, et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflam-matory changes in the interaction between adipo-cytes and macrophages. Arterioscler Thromb Vasc Biol. 2007; 27: 84-91
|
|
|
|
|
|
13) Shimomura I, et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999; 401: 73-6
|
|
|
|
|
|
14) Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-6
|
|
|
|
|
|
15) Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PPARγameliorates diet-induced-obesity and type 2 diabetes. J Clin Invest. 2001; 108: 1001-13
|
|
|
|
|
|
16) Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resist-ance and neointimal formation. J Biol Chem. 2002; 277: 25863-6
|
|
|
|
|
|
17) Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vaso-reactivity. Hypertension. 2003; 42: 231-4
|
|
|
|
|
|
18) Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003; 278: 2461-8
|
|
|
|
|
|
19) Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-95
|
|
|
|
|
|
20) Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-9
|
|
|
|
|
|
21) Tsuchida A, Yamauchi T, Ito Y, et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004; 279: 30817-22
|
|
|
|
|
|
22) Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13: 332-9
|
|
|
|
|